towards improved death receptor targeted therapy for ... - TI Pharma

More documents

Recommendations

Info

Non‐canonical TRAIL signaling activates c‐Jun NH2‐terminal kinase (JNK) via caspase‐dependent and caspase‐ independent pathways. J Biol Chem 1998; 273(49):33091‐33098. 56. Herr I, Wilhelm D, Meyer E, Jeremias I, Angel P, Debatin KM. JNK/SAPK activity contributes to TRAIL‐induced apoptosis. Cell Death Differ 1999; 6(2):130‐135. 57. Hu WH, Johnson H, Shu HB. Tumor necrosis factor‐related apoptosis‐inducing ligand receptors signal NF‐kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274(43):30603‐30610. 58. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S et al. The death domain kinase RIP is essential for TRAIL (Apo2L)‐induced activation of IkappaB kinase and c‐Jun N‐ terminal kinase. Mol Cell Biol 2000; 20(18):6638‐6645. 59. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D et al. TRAIL receptor‐mediated JNK activation and Bim phosphorylation critically regulate Fas‐mediated liver damage and lethality. J Clin Invest 2006; 116(9):2493‐2499. 60. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor‐ related apoptosis‐inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl‐2 proteins. J Biol Chem 2007; 282(39):28960‐28970. 61. Park KJ, Lee SH, Lee CH, Jang JY, Chung J, Kwon MH et al. Upregulation of Beclin‐1 expression and phosphorylation of Bcl‐2 and p53 are involved in the JNK‐mediated autophagic cell death. Biochem Biophys Res Commun 2009; 382(4):726‐729. 62. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22(13):2034‐2044. 63. Mucha SR, Rizzani A, Gerbes AL, Camaj P, Thasler WE, Bruns CJ et al. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF‐related apoptosis‐inducing ligand. Gut 2009; 58(5):688‐698. 64. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 2006; 21(5):701‐710. 65. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer 2009; 100(9):1415‐1424. 66. Lee MW, Park SC, Yang YG, Yim SO, Chae HS, Bach JH et al. The involvement of reactive oxygen species (ROS) and p38 mitogen‐activated protein (MAP) kinase in TRAIL/Apo2L‐ induced apoptosis. FEBS Lett 2002; 512(1‐3):313‐318. 67. Zhang L, Zhu H, Davis JJ, Jacob D, Wu S, Teraishi F et al. Lack of p38 MAP kinase activation in TRAIL‐resistant cells is not related to the resistance to TRAIL‐mediated cell death. Cancer Biol Ther 2004; 3(3):296‐301. 68. Son JK, Varadarajan S, Bratton SB. TRAIL‐activated stress kinases suppress apoptosis through transcriptional upregulation of MCL‐1. Cell Death Differ 2010; 17(8):1288‐1301. 69. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE et al. Sensitization of apoptotically‐resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen‐activated protein kinase signaling. Int J Oncol 2004; 24(6):1473‐1480. 70. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P et al. Tumour necrosis factor‐related apoptosis‐inducing ligand sequentially activates pro‐survival and pro‐ apoptotic pathways in SK‐N‐MC neuronal cells. J Neurochem 2003; 86(1):126‐135. 71. Vaculova A, Hofmanova J, Soucek K, Kozubik A. Different modulation of TRAIL‐induced apoptosis by inhibition of pro‐survival pathways in TRAIL‐sensitive and TRAIL‐resistant colon cancer cells. FEBS Lett 2006; 580(28‐29):6565‐6569. 72. Belyanskaya LL, Ziogas A, Hopkins‐Donaldson S, Kurtz S, Simon HU, Stahel R et al. TRAIL‐ induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL‐R2/DR5 expression in the absence of caspase‐8. Lung Cancer 2008; 60(3):355‐365. 73. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P. Activation of ERK1/2 protects ‐ 35 ‐
Chapter 2 melanoma cells from TRAIL‐induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003; 22(19):2869‐2881. 74. Vilimanovich U, Bumbasirevic V. TRAIL induces proliferation of human glioma cells by c‐ FLIPL‐mediated activation of ERK1/2. Cell Mol Life Sci 2008; 65(5):814‐826. 75. Song JJ, Lee YJ. Differential cleavage of Mst1 by caspase‐7/‐3 is responsible for TRAIL‐ induced activation of the MAPK superfamily. Cell Signal 2008; 20(5):892‐906. 76. Sun BK, Kim JH, Nguyen HN, Kim SY, Oh S, Lee YJ et al. TRAIL‐induced caspase/p38 activation is responsible for the increased catalytic and invasive activities of Akt. Int J Oncol 2011; 38(1):249‐256. 77. Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S et al. Blockade of transforming growth factor‐beta‐activated kinase 1 activity enhances TRAIL‐induced apoptosis through activation of a caspase cascade. Mol Cancer Ther 2006; 5(12):2970‐ 2976. 78. Morioka S, Omori E, Kajino T, Kajino‐Sakamoto R, Matsumoto K, Ninomiya‐Tsuji J. TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene 2009; 28(23):2257‐2265. 79. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S et al. CD95 and TRAIL receptor‐mediated activation of protein kinase C and NF‐kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20(31):4258‐4269. 80. Gillespie S, Zhang XD, Hersey P. Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL‐induced apoptosis. Mol Cancer Ther 2005; 4(4):668‐676. 81. Shankar E, Sivaprasad U, Basu A. Protein kinase C epsilon confers resistance of MCF‐7 cells to TRAIL by Akt‐dependent activation of Hdm2 and downregulation of p53. Oncogene 2008; 27(28):3957‐3966. 82. Harper N, Hughes MA, Farrow SN, Cohen GM, MacFarlane M. Protein kinase C modulates tumor necrosis factor‐related apoptosis‐inducing ligand‐induced apoptosis by targeting the apical events of death receptor signaling. J Biol Chem 2003; 278(45):44338‐44347. 83. Farrow B, Thomas RP, Wang XF, Evers BM. Activation of conventional PKC isoforms increases expression of the pro‐apoptotic protein Bad and TRAIL receptors. Int J Gastrointest Cancer 2002; 32(2‐3):63‐72. 84. Fresno Vara JA, Casado E, de CJ, Cejas P, Belda‐Iniesta C, Gonzalez‐Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30(2):193‐204. 85. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di PR. PI‐3K/Akt and NF‐ kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 2005; 202(3):900‐911. 86. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF‐kappaB activation by tumour necrosis factor requires the Akt serine‐threonine kinase. Nature 1999; 401(6748):82‐85. 87. Wang D, Baldwin AS, Jr. Activation of nuclear factor‐kappaB‐dependent transcription by tumor necrosis factor‐alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem 1998; 273(45):29411‐29416. 88. Tanaka H, Fujita N, Tsuruo T. 3‐Phosphoinositide‐dependent protein kinase‐1‐mediated IkappaB kinase beta (IkkB) phosphorylation activates NF‐kappaB signaling. J Biol Chem 2005; 280(49):40965‐40973. 89. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010; 5(4):e10226. 90. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J et al. Kinome profiling of non‐canonical TRAIL signaling reveals RIP1‐Src‐STAT3 dependent invasion in resistant non‐small cell lung cancer cells. J Cell Sci 2012. 91. Song JJ, Kim JH, Sun BK, Alcala MA, Jr., Bartlett DL, Lee YJ. c‐Cbl acts as a mediator of Src‐ ‐ 36 ‐
Page 2 and 3: TRAIL-induced kinases activation an
Page 4 and 5: TRAIL‐induced kinases activation
Page 6: “In order to be irreplaceable one
Page 9 and 10: ‐ 8 ‐
Page 11 and 12: Chapter 1 GENERAL INTRODUCTION Canc
Page 13 and 14: Chapter 1 OUTLINE OF THE THESIS As
Page 15 and 16: Chapter 1 Reference List 1. Jemal A
Page 17 and 18: Chapter 2 ABSTRACT Tumor necrosis f
Page 19 and 20: Chapter 2 INTRODUCTION The death li
Page 21 and 22: Chapter 2 In preclinical studies, a
Page 23 and 24: Chapter 2 Table 1| Summary of the k
Page 25 and 26: Chapter 2 proliferation could be pr
Page 27 and 28: Chapter 2 Figure 2. Canonical and n
Page 29 and 30: Chapter 2 associated with TRAIL res
Page 31 and 32: Chapter 2 adhesion molecules [109].
Page 33 and 34: Chapter 2 Reference List 1. Ashkena
Page 35: Chapter 2 37. Tolcher AW, Mita M, M
Page 39 and 40: Chapter 2 and ERK pathways. Circula
Page 43 and 44: Chapter 3 inhibitors and TRAIL rece
Page 45 and 46: Chapter 3 of amplification of the t
Page 47 and 48: Chapter 3 P38 and JNK have opposing
Page 49 and 50: Chapter 3 Figure 2 (continued). (e)
Page 51 and 52: Chapter 3 previously established H4
Page 53 and 54: Chapter 3 effect on TRAIL‐induced
Page 55 and 56: Chapter 3 induced apoptosis in H460
Page 57 and 58: Chapter 3 Reference List 1. Jemal A
Page 59 and 60: Chapter 3 40. Domina AM, Vrana JA,
Page 63 and 64: Chapter 4 role in the activation of
Page 65 and 66: Chapter 4 the tip with a diameter o
Page 67 and 68: Chapter 4 RESULTS TRAIL induces a s
Page 69 and 70: Chapter 4 vehicle control or with 5
Page 71 and 72: Chapter 4 Non‐canonical TRAIL res
Page 73 and 74: Chapter 4 A549‐shRIP1 cells clear
Page 75 and 76: Chapter 4 Figure 7. Inhibition of S
Page 77 and 78: Chapter 4 DISCUSSION The TRAIL rece
Page 79 and 80: Chapter 4 Src‐independent mechani
Page 81 and 82: Chapter 4 variants. Cell Death Dis
Page 83 and 84: Chapter 4 ‐ 82 ‐
Page 85 and 86: Chapter 5 ABSTRACT TRAIL is an inte
Page 87 and 88:
Chapter 5 targets and subsequent pr
Page 89 and 90:
Chapter 5 RESULTS Synergistic activ
Page 91 and 92:
Chapter 5 ng/ml TRAIL (Fig. 3B). Ap
Page 93 and 94:
Chapter 5 by sub‐G1 levels in the
Page 95 and 96:
Chapter 5 DISCUSSION In the present
Page 97 and 98:
Chapter 5 Reference List 1. Jemal A
Page 99 and 100:
Chapter 5 ‐ 98 ‐
Page 101 and 102:
Chapter 6 ABSTRACT TRAIL is a tumor
Page 103 and 104:
Chapter 6 various stress stimuli [1
Page 105 and 106:
Chapter 6 Subsequently, the membran
Page 107 and 108:
Chapter 6 B H460 A549 Figure 1. Rep
Page 109 and 110:
Chapter 6 TRAIL‐dependent cell de
Page 111 and 112:
Chapter 6 B H460 A549 C Figure 4 (c
Page 113 and 114:
Chapter 6 Figure 5 (continued). Mec
Page 115 and 116:
Chapter 6 regulation and checkpoint
Page 117 and 118:
Chapter 6 mechanism of immune evasi
Page 119 and 120:
Chapter 7 ABSTRACT Thymidine phosph
Page 121 and 122:
Chapter 7 Figure 1. Schematic overv
Page 123 and 124:
Chapter 7 that was measured before
Page 125 and 126:
Chapter 7 RESULTS TdR conversion to
Page 127 and 128:
Chapter 7 dR is secreted from the c
Page 129 and 130:
Chapter 7 Figure 4. Accumulation of
Page 131 and 132:
Chapter 7 angiogenic properties. Ho
Page 133 and 134:
Chapter 7 activity of enzymes. Natu
Page 135 and 136:
Page 137 and 138:
Chapter 8 SUMMARIZING DISCUSSION AN
Page 139 and 140:
Chapter 8 Recently, various differe
Page 141 and 142:
Chapter 8 in phase II clinical tria
Page 143 and 144:
Chapter 8 Reference List 1. Herbst
Page 145 and 146:
Page 147 and 148:
Chapter 9 NEDERLANDSE SAMENVATTING
Page 149 and 150:
Chapter 9 waargenomen. Het gebruik
Page 151 and 152:
Chapter 9 CONCLUSIE Het activeren v
Page 153 and 154:
zelfs na werktijden (lees 23:45) ko
Page 155 and 156:
Verder wil ik ook dr. Eric Ronken b
show all

towards improved death receptor targeted therapy for ... - TI Pharma

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?